Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-[1-(aminomethyl)cyclopropyl]-3-(morpholin-4-ylsulfonyl)-N~2~-[(1S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]-L-alaninamide
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound is a synthetic small molecule with the chemical formula C19H26F4N4O4S and a molecular weight of 482.5 g/mol. It is listed in pharmaceutical screening libraries and databases such as PubChem and ZINC15[1][6]. The structure features a cyclopropane ring substituted with an aminomethyl group, a morpholine sulfonamide moiety, and a trifluorinated phenylethyl side chain attached to an L-alaninamide core. While it appears in drug screening collections as DB07520/C28 for research purposes[6][8], there is no evidence that it has been developed or approved for clinical use or that it has reached any stage of pharmaceutical development beyond being catalogued as a potential bioactive compound.
- Other names
- (2R)-N-(1-(aminomethyl)cyclopropyl)-3-(morpholine-4-sulfonyl)-2-(((1S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl)amino)propanamide(2R)-N-[1-(aminomethyl)cyclopropyl]-3-(morpholine-4-sulfonyl)-2-{[(1S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]amino}propanamide
Beyond the preview
Go deeper on N-[1-(aminomethyl)cyclopropyl]-3-(morpholin-4-ylsulfonyl)-N~2~-[(1S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]-L-alaninamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-[1-(aminomethyl)cyclopropyl]-3-(morpholin-4-ylsulfonyl)-N~2~-[(1S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]-L-alaninamide.